D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Biology and Biochemistry D-index 100 Citations 36,598 408 World Ranking 1010 National Ranking 627

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Enzyme
  • DNA

His scientific interests lie mostly in RNA, Oligonucleotide, Biochemistry, RNase P and RNase H. His study looks at the intersection of RNA and topics like Cell biology with Gene expression and Messenger RNA. His work on Antisense oligonucleotides as part of general Oligonucleotide study is frequently connected to Mechanism, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.

His work on Nuclease, Enzyme, Binding site and Binding selectivity as part of general Biochemistry study is frequently linked to Ribostamycin, therefore connecting diverse disciplines of science. His research on RNase P frequently links to adjacent areas such as Molecular biology. His RNase H study integrates concerns from other disciplines, such as Cleavage and RNase MRP.

His most cited work include:

  • Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents: A COMPARATIVE ANALYSIS * (705 citations)
  • Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. (674 citations)
  • Progress in Antisense Technology (425 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Oligonucleotide, RNA, Molecular biology, Biochemistry and RNase P. His research investigates the connection with Oligonucleotide and areas like Computational biology which intersect with concerns in Drug discovery. His studies in RNA integrate themes in fields like Gene silencing and Function, Cell biology.

The Molecular biology study combines topics in areas such as RNA-induced silencing complex, Small interfering RNA, Messenger RNA, Gene and Nuclease protection assay. His RNase P study combines topics in areas such as Cleavage and DNA. As a part of the same scientific study, Stanley T. Crooke usually deals with the Antisense oligonucleotides, concentrating on Pharmacology and frequently concerns with Apolipoprotein B.

He most often published in these fields:

  • Oligonucleotide (35.96%)
  • RNA (30.34%)
  • Molecular biology (28.09%)

What were the highlights of his more recent work (between 2011-2021)?

  • Oligonucleotide (35.96%)
  • Cell biology (19.66%)
  • RNA (30.34%)

In recent papers he was focusing on the following fields of study:

Stanley T. Crooke mostly deals with Oligonucleotide, Cell biology, RNA, RNase P and Molecular biology. His Oligonucleotide study is related to the wider topic of Biochemistry. His Cell biology study incorporates themes from Cell and RNA splicing.

His biological study spans a wide range of topics, including Regulation of gene expression, Computational biology, Gene expression and Recombinant DNA. His work deals with themes such as Locked nucleic acid, Messenger RNA, Transcription and Antisense Technology, which intersect with RNase P. Stanley T. Crooke combines subjects such as Cytoplasm, Exosome complex, Small interfering RNA, RNA silencing and RNase MRP with his study of Molecular biology.

Between 2011 and 2021, his most popular works were:

  • Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials (361 citations)
  • Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans (258 citations)
  • Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression (233 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Enzyme
  • DNA

Stanley T. Crooke mainly focuses on RNA, Oligonucleotide, RNase P, Molecular biology and Cell biology. His research in RNA intersects with topics in Gene silencing and Gene expression. Oligonucleotide is a primary field of his research addressed under Biochemistry.

His work in the fields of Biochemistry, such as Phosphorothioate Oligonucleotides and Nuclease, intersects with other areas such as Endocytosis Pathway. His RNase P research includes themes of Locked nucleic acid, Cytoplasm and Messenger RNA. His work in Cell biology covers topics such as Paraspeckle which are related to areas like Small nuclear RNA, RNA silencing and Non-coding RNA.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Frederick J Raal;Raul D Santos;Dirk J Blom;A David Marais.
The Lancet (2010)

1138 Citations

Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents: A COMPARATIVE ANALYSIS *

Timothy A. Vickers;Seongjoon Koo;C. Frank Bennett;Stanley T. Crooke.
Journal of Biological Chemistry (2003)

1116 Citations

Oligoribonucleotides and ribonucleases for cleaving RNA

Stanley T. Crooke.
(1997)

660 Citations

Progress in Antisense Technology

Stanley T. Crooke.
Annual Review of Medicine (2004)

653 Citations

Molecular mechanisms of action of antisense drugs.

Stanley T Crooke.
Biochimica et Biophysica Acta (1999)

559 Citations

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Nicholas J Viney;Julian C van Capelleveen;Richard S Geary;Shuting Xia.
The Lancet (2016)

538 Citations

Oligoribonucleotides for cleaving RNA

Stanley T. Crooke.
(1996)

511 Citations

Therapeutic applications of oligonucleotides.

Stanley T. Crooke.
Annual Review of Pharmacology and Toxicology (1992)

480 Citations

Progress in antisense oligonucleotide therapeutics.

S T Crooke;C F Bennett.
Annual Review of Pharmacology and Toxicology (1996)

478 Citations

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

Mark J. Graham;Kristina M. Lemonidis;Charles P. Whipple;Amuthakannan Subramaniam.
Journal of Lipid Research (2007)

471 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Stanley T. Crooke

Eric E. Swayze

Eric E. Swayze

Ionis Pharmaceuticals (United States)

Publications: 116

Anastasia Khvorova

Anastasia Khvorova

University of Massachusetts Medical School

Publications: 92

David J. Ecker

David J. Ecker

Ionis Pharmaceuticals (United States)

Publications: 89

C. Frank Bennett

C. Frank Bennett

Ionis Pharmaceuticals (United States)

Publications: 81

Muthiah Manoharan

Muthiah Manoharan

Alnylam Pharmaceuticals (United States)

Publications: 76

Rangarajan Sampath

Rangarajan Sampath

Ionis Pharmaceuticals (United States)

Publications: 73

Gerald F. Watts

Gerald F. Watts

University of Western Australia

Publications: 73

Punit P. Seth

Punit P. Seth

Ionis Pharmaceuticals (United States)

Publications: 70

Sotirios Tsimikas

Sotirios Tsimikas

University of California, San Diego

Publications: 68

Richard S. Geary

Richard S. Geary

Ionis Pharmaceuticals (United States)

Publications: 63

Brett P. Monia

Brett P. Monia

Ionis Pharmaceuticals (United States)

Publications: 55

Martin E. Gleave

Martin E. Gleave

University of British Columbia

Publications: 46

David R. Corey

David R. Corey

The University of Texas Southwestern Medical Center

Publications: 42

Nicholas M. Dean

Nicholas M. Dean

Ionis Pharmaceuticals (United States)

Publications: 41

Robert Langer

Robert Langer

MIT

Publications: 35

Joseph L. Witztum

Joseph L. Witztum

University of California, San Diego

Publications: 33

Trending Scientists

Benjamin Friedlander

Benjamin Friedlander

University of California, Santa Cruz

Edith Ngai

Edith Ngai

University of Hong Kong

Srinivas Garimella

Srinivas Garimella

Georgia Institute of Technology

Peter Auer

Peter Auer

University of Leoben

Hongzhou Lian

Hongzhou Lian

Chinese Academy of Sciences

James F. Ranville

James F. Ranville

Colorado School of Mines

Patrick Argos

Patrick Argos

Purdue University West Lafayette

Yves Brunet

Yves Brunet

INRAE : Institut national de recherche pour l'agriculture, l'alimentation et l'environnement

Michele K. Dougherty

Michele K. Dougherty

Imperial College London

Jonathan W. Uhr

Jonathan W. Uhr

The University of Texas Southwestern Medical Center

Michael E. Saladin

Michael E. Saladin

Medical University of South Carolina

Robert Terkeltaub

Robert Terkeltaub

University of California, San Diego

Daniel I. Rosenthal

Daniel I. Rosenthal

Harvard University

David Roe

David Roe

University of Haifa

Diane Stone

Diane Stone

Central European University

Daniel A. Perley

Daniel A. Perley

Liverpool John Moores University

Something went wrong. Please try again later.